URGN
UroGen Pharma Ltd.
+0.78 (+1.79%)44.27USD295K成交股數–市值–本益比(近四季)–股價營收比+199.2%營收年增(近四季)2026-11-05下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 5 · 3.7M · 2 |
| 其中 10b5-1 計畫賣出 | 2 筆 |
| 近 180 天 買進 · 賣出金額 | 0 · 4.1M |
| 近 180 天 淨額 | −4.1M |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-08 | 09-09 | Smith Jason Drew | General Counsel | S 公開市場賣出 | 1.5K | 42.54 | 65K | 53.1K | SEC |
| 2026-09-08 | 09-09 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 871 | 42.92 | 37K | 59.9K | SEC |
| 2026-09-07 | 09-09 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 1.7K | – | – | 60.8K | SEC |
| 2026-09-07 | 09-09 | Smith Jason Drew | General Counsel | M 選擇權執行 | 3.3K | – | – | 54.7K | SEC |
| 2026-08-26 | 08-28 | Robinson James A. Jr. | Director | M 選擇權執行 | 2.0K | – | – | 8.0K | SEC |
| 2026-08-20 | 08-24 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 60.7K | 47.05 | 2.9M | 59.1K | SEC |
| 2026-07-09 | 07-10 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出(10b5-1) | 10.0K | 40.00 | 400K | 120K | SEC |
| 2026-06-22 | 06-24 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出(10b5-1) | 10.0K | 35.01 | 350K | 130K | SEC |
| 2026-06-08 | 06-09 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 5.2K | 27.30 | 143K | 140K | SEC |
| 2026-06-08 | 06-09 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 10.0K | – | – | 145K | SEC |
| 2026-05-26 | 05-27 | Robinson James A. Jr. | Director | M 選擇權執行 | 2.0K | – | – | 6.0K | SEC |
| 2026-05-08 | 05-11 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出(10b5-1) | 10.0K | 30.00 | 300K | 135K | SEC |
| 2026-02-03 | 02-11 | Smith Jason Drew | General Counsel | S 公開市場賣出 | 2.7K | 19.69 | 52K | 52.9K | SEC |
| 2026-02-03 | 02-11 | Smith Jason Drew | General Counsel | S 公開市場賣出 | 3.2K | 19.69 | 63K | 55.6K | SEC |
| 2026-02-03 | 02-11 | Smith Jason Drew | General Counsel | S 公開市場賣出 | 1.6K | 19.69 | 32K | 51.3K | SEC |
| 2026-02-03 | 02-04 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 1.8K | 19.69 | 36K | 151K | SEC |
| 2026-02-03 | 02-04 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 1.8K | 19.69 | 36K | 149K | SEC |
| 2026-02-03 | 02-04 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 3.7K | 19.69 | 73K | 145K | SEC |
| 2026-01-31 | 02-11 | Smith Jason Drew | General Counsel | M 選擇權執行 | 5.5K | – | – | 55.5K | SEC |
| 2026-01-31 | 02-11 | Smith Jason Drew | General Counsel | M 選擇權執行 | 3.3K | – | – | 58.8K | SEC |
| 2026-01-31 | 02-11 | Smith Jason Drew | General Counsel | M 選擇權執行 | 6.7K | – | – | 50.0K | SEC |
| 2026-01-31 | 02-03 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 6.7K | – | – | 152K | SEC |
| 2026-01-31 | 02-03 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 3.3K | – | – | 142K | SEC |
| 2026-01-31 | 02-03 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 3.3K | – | – | 146K | SEC |
| 2025-11-26 | 12-01 | Holden Stuart | Director | M 選擇權執行 | 2.0K | – | – | 2.0K | SEC |
| 2025-11-26 | 12-01 | Wildman Daniel George | Director | M 選擇權執行 | 2.0K | – | – | 2.0K | SEC |
| 2025-11-26 | 12-01 | WEN LEANA | Director | M 選擇權執行 | 2.0K | – | – | 2.0K | SEC |
| 2025-11-26 | 12-01 | Robinson James A. Jr. | Director | M 選擇權執行 | 2.0K | – | – | 2.0K | SEC |
| 2025-11-26 | 12-01 | BUTITTA CYNTHIA M | Director | M 選擇權執行 | 2.0K | – | – | 2.0K | SEC |
| 2025-11-19 | 11-20 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出(10b5-1) | 10.0K | 25.00 | 250K | 139K | SEC |
| 2025-10-08 | 10-09 | Degnan Chris | Chief Financial Officer | S 公開市場賣出 | 2.2K | 16.85 | 37K | 2.3K | SEC |
| 2025-10-08 | 10-09 | Degnan Chris | Chief Financial Officer | M 選擇權執行 | 4.5K | – | – | 4.5K | SEC |
| 2025-09-08 | 09-09 | Smith Jason Drew | General Counsel | S 公開市場賣出 | 1.5K | 19.11 | 29K | 43.3K | SEC |
| 2025-09-08 | 09-09 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 871 | 19.11 | 17K | 149K | SEC |
| 2025-09-07 | 09-09 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 1.7K | – | – | 150K | SEC |
| 2025-09-07 | 09-09 | Smith Jason Drew | General Counsel | M 選擇權執行 | 3.3K | – | – | 44.8K | SEC |
| 2025-08-11 | 08-13 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 10.0K | 17.69 | 177K | 148K | SEC |
| 2025-07-28 | 07-30 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 10.0K | – | – | 163K | SEC |
| 2025-07-28 | 07-30 | Smith Jason Drew | General Counsel | S 公開市場賣出 | 7.5K | 19.14 | 144K | 41.5K | SEC |
| 2025-07-28 | 07-30 | Smith Jason Drew | General Counsel | M 選擇權執行 | 16.5K | – | – | 49.0K | SEC |
| 2025-07-28 | 07-30 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 5.1K | 19.14 | 99K | 158K | SEC |
| 2025-06-09 | 06-11 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 5.2K | 7.37 | 38K | 153K | SEC |
| 2025-06-08 | 06-11 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 10.0K | – | – | 159K | SEC |
| 2025-02-26 | 02-27 | Robinson James A. Jr. | Director | M 選擇權執行 | 2.0K | – | – | 4.0K | SEC |
| 2025-01-31 | 02-04 | Smith Jason Drew | General Counsel | S 公開市場賣出 | 3.4K | 11.14 | 37K | 29.8K | SEC |
| 2025-01-31 | 02-04 | Smith Jason Drew | General Counsel | M 選擇權執行 | 2.5K | – | – | 27.7K | SEC |
| 2025-01-31 | 02-04 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 1.9K | 11.14 | 21K | 149K | SEC |
| 2025-01-31 | 02-04 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 1.9K | 11.14 | 21K | 147K | SEC |
| 2025-01-31 | 02-04 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 3.3K | – | – | 149K | SEC |
| 2025-01-31 | 02-04 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 759 | 11.14 | 8K | 146K | SEC |
| 2025-01-31 | 02-04 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 1.3K | – | – | 146K | SEC |
| 2025-01-31 | 02-04 | Smith Jason Drew | General Counsel | S 公開市場賣出 | 2.8K | 11.14 | 31K | 32.5K | SEC |
| 2025-01-31 | 02-04 | Smith Jason Drew | General Counsel | M 選擇權執行 | 5.5K | – | – | 35.3K | SEC |
| 2025-01-31 | 02-04 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 3.3K | – | – | 150K | SEC |
| 2025-01-31 | 02-04 | Smith Jason Drew | General Counsel | M 選擇權執行 | 6.7K | – | – | 33.1K | SEC |
| 2025-01-31 | 02-04 | Smith Jason Drew | General Counsel | S 公開市場賣出 | 1.3K | 11.14 | 14K | 26.5K | SEC |
| 2024-09-09 | 09-12 | Smith Jason Drew | General Counsel | S 公開市場賣出 | 1.5K | 13.08 | 20K | 25.2K | SEC |
| 2024-09-09 | 09-12 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 859 | 13.08 | 11K | 145K | SEC |
| 2024-09-09 | 09-12 | Smith Jason Drew | General Counsel | M 選擇權執行 | 3.3K | – | – | 26.7K | SEC |
| 2024-09-09 | 09-12 | Kim Dong | Chief Financial Officer | M 選擇權執行 | 2.5K | – | – | 37.8K | SEC |
| 2024-09-09 | 09-12 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 1.7K | – | – | 146K | SEC |
| 2024-06-10 | 06-11 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 5.2K | 13.08 | 67K | 144K | SEC |
| 2024-06-10 | 06-11 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 10.0K | – | – | 149K | SEC |
| 2024-03-18 | 03-20 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 12.0K | 14.05 | 169K | 139K | SEC |
| 2024-02-01 | 02-05 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 758 | 15.78 | 12K | 150K | SEC |
| 2024-02-01 | 02-05 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 1.1K | 15.78 | 18K | 149K | SEC |
| 2024-02-01 | 02-05 | Smith Jason Drew | General Counsel | S 公開市場賣出 | 3.3K | 15.78 | 53K | 23.4K | SEC |
| 2024-02-01 | 02-05 | Smith Jason Drew | General Counsel | S 公開市場賣出 | 1.2K | 15.78 | 20K | 20.1K | SEC |
| 2024-02-01 | 02-05 | Smith Jason Drew | General Counsel | S 公開市場賣出 | 417 | 15.78 | 7K | 18.8K | SEC |
| 2024-02-01 | 02-05 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 1.9K | 15.78 | 30K | 151K | SEC |
| 2024-01-31 | 02-12 | Kim Dong | Chief Financial Officer | M 選擇權執行 | 3.3K | – | – | 35.3K | SEC |
| 2024-01-31 | 02-02 | Smith Jason Drew | General Counsel | S 公開市場賣出 | 417 | 15.74 | 7K | 18.8K | SEC |
| 2024-01-31 | 02-02 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 1.9K | 15.74 | 30K | 151K | SEC |
| 2024-01-31 | 02-02 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 3.3K | – | – | 153K | SEC |
| 2024-01-31 | 02-02 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 758 | 15.74 | 12K | 150K | SEC |
| 2024-01-31 | 02-02 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 1.3K | – | – | 151K | SEC |
| 2024-01-31 | 02-02 | Schoenberg Mark | Chief Medical Officer | S 公開市場賣出 | 1.1K | 15.74 | 18K | 149K | SEC |
| 2024-01-31 | 02-02 | Smith Jason Drew | General Counsel | M 選擇權執行 | 834 | – | – | 19.2K | SEC |
| 2024-01-31 | 02-02 | Schoenberg Mark | Chief Medical Officer | M 選擇權執行 | 2.0K | – | – | 151K | SEC |
| 2024-01-31 | 02-02 | Kim Dong | Chief Financial Officer | M 選擇權執行 | 3.3K | – | – | 26.6K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 4.5M | 167M | 不變 | 持平 |
| BlackRock, Inc. | 3.2M | 118M | +356K (+13%) | 加碼 |
| MORGAN STANLEY | 2.6M | 94.8M | +16.3K (+1%) | 加碼 |
| Kynam Capital Management, LP | 2.4M | 89.6M | +187K (+8%) | 加碼 |
| Jefferies Financial Group Inc. | 2.2M | 80.9M | 不變 | 持平 |
| AMERICAN CENTURY COMPANIES INC | 1.7M | 62.0M | +48.1K (+3%) | 加碼 |
| ACORN CAPITAL ADVISORS, LLC | 1.7M | 61.6M | 不變 | 持平 |
| Point72(柯恩) Point72 Asset Management, L.P. | 1.5M | 56.1M | 新進 | 新進 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 1.5M | 55.5M | +194K (+15%) | 加碼 |
| Opaleye Management Inc. | 1.4M | 53.0M | +10.0K (+1%) | 加碼 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.3M | 47.9M | −201K (-13%) | 減碼 |
| MENORA MIVTACHIM HOLDINGS LTD. | 1.2M | 42.4M | 不變 | 持平 |
| 德劭 D. E. Shaw & Co., Inc. | 1.1M | 42.2M | +123K (+12%) | 加碼 |
| STATE STREET CORP | 1.0M | 36.9M | +129K (+15%) | 加碼 |
| MPM BIOIMPACT LLC | 933K | 34.3M | −10.4K (-1%) | 減碼 |
| Soleus Capital Management, L.P. | 830K | 30.5M | +103K (+14%) | 加碼 |
| GOLDMAN SACHS GROUP INC | 820K | 30.2M | +221K (+37%) | 加碼 |
| Migdal Insurance & Financial Holdings Ltd. | 771K | 28.4M | 不變 | 持平 |
| ORBIMED ADVISORS LLC | 676K | 24.9M | −199K (-23%) | 減碼 |
| GEODE CAPITAL MANAGEMENT, LLC | 610K | 22.5M | +86.5K (+17%) | 加碼 |
| Woodline Partners LP | 501K | 18.4M | 不變 | 持平 |
| Boxer Capital Management, LLC | 500K | 18.4M | 不變 | 持平 |
| BANK OF AMERICA CORP /DE/ | 476K | 17.5M | +349K (+275%) | 加碼 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 457K | 16.8M | +47.0K (+11%) | 加碼 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 387K | 14.2M | 不變 | 持平 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 190 +16 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 40 / 24 / 58 / 52 |
| 機構合計持股 · 佔流通股 | 42.4M |
| 合計季末市值 | 1.5B |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 6.2M |
|---|---|
| 與上期比 | +22.0% |
| 佔流通股數 | –(外國發行人不算) |
| 日均成交量 | 919K |
| 回補天數 | 6.8 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 6.2M | +22.0% | – | 919K | 6.8 |
| 2026-08-14 | 5.1M | +11.6% | – | 1.1M | 4.8 |
| 2026-07-31 | 4.6M | -19.3% | – | 692K | 6.6 |
| 2026-07-15 | 5.7M | -8.5% | – | 825K | 6.9 |
| 2026-06-30 | 6.2M | -5.2% | – | 660K | 9.4 |
| 2026-06-15 | 6.6M | -5.3% | – | 664K | 9.9 |
| 2026-05-29 | 6.9M | +2.3% | – | 624K | 11.1 |
| 2026-05-15 | 6.8M | -6.5% | – | 1.2M | 5.8 |
| 2026-04-30 | 7.2M | -7.5% | – | 815K | 8.9 |
| 2026-04-15 | 7.8M | -6.3% | – | 699K | 11.2 |
| 2026-03-31 | 8.3M | -3.3% | – | 706K | 11.8 |
| 2026-03-13 | 8.6M | +7.6% | – | 1.1M | 7.8 |
| 2026-02-27 | 8.0M | -14.1% | – | 740K | 10.8 |
| 2026-02-13 | 9.3M | -9.3% | – | 617K | 15.1 |
| 2026-01-30 | 10.3M | -2.5% | – | 707K | 14.6 |
| 2026-01-15 | 10.6M | +10.8% | – | 728K | 14.5 |
| 2025-12-31 | 9.5M | +23.3% | – | 705K | 13.5 |
| 2025-12-15 | 7.7M | -2.6% | – | 938K | 8.3 |
| 2025-11-28 | 8.0M | -11.4% | – | 1.1M | 7.3 |
| 2025-11-14 | 9.0M | -20.4% | – | 1.7M | 5.3 |
| 2025-10-31 | 11.3M | +1.2% | – | 832K | 13.6 |
| 2025-10-15 | 11.1M | +27.9% | – | 1.1M | 10.0 |
| 2025-09-30 | 8.7M | +9.7% | – | 1.2M | 7.3 |
| 2025-09-15 | 7.9M | +13.2% | – | 1.3M | 5.9 |
| 2025-08-29 | 7.0M | +2.2% | – | 945K | 7.4 |
| 2025-08-15 | 6.9M | -4.1% | – | 1.2M | 5.9 |